Yamo Pharmaceuticals is addressing a critical unmet need in Autism Spectrum Disorder (ASD) treatment with L1-79, an innovative therapy designed to target core deficits in social-interaction. L1-79 has been well-tolerated in clinical trials. The efficacy demonstrated in Yamo's most recent Phase 2 study which concluded in July 2024 could represent a significant advancement for individuals with ASD.
The mechanism of action of L1-79 focuses on regulating catecholamine networks, targeting key pathways in both the central and autonomic nervous systems. This approach aims to enhance communication and social behavior, offering new hope for those affected by ASD.
